Business Wire05.21.19
Galt Medical, a subsidiary of Theragenics Corporation and a global supplier of access and procedure products for a range of interventional and endovascular procedures, today announced it has acquired Arrotek Medical Limited. Arrotek, located in Sligo, Ireland, develops and designs minimally invasive medical devices supporting a range of catheter-based, interventional applications. Arrotek’s capabilities include concept, design, product development, regulatory approval, and certain manufacturing services. Mark Pugh and Ger O’Carroll, co-founders of Arrotek, will remain with Arrotek in Sligo as co-Managing Directors.
Frank Attardo, president of Galt Medical, commented, “The capabilities of Arrotek and Galt are highly complementary to each other. Arrotek’s product development capabilities, combined with Galt’s manufacturing and processing capabilities, will allow the combined company to better serve existing customers and address and serve a wider segment of the interventional market.”
Mark Pugh and Ger O’Carroll commented, “Galt provides Arrotek with access to markets, capabilities, and expertise previously unavailable to us. The combination with Galt will benefit existing customers of both companies, as well as provide Arrotek with opportunities to serve new segments of the market in Europe, North America and other global markets. Becoming part of the larger Theragenics organization also provides the resources to accelerate our growth and continue to expand.”
Frank Attardo, president of Galt Medical, commented, “The capabilities of Arrotek and Galt are highly complementary to each other. Arrotek’s product development capabilities, combined with Galt’s manufacturing and processing capabilities, will allow the combined company to better serve existing customers and address and serve a wider segment of the interventional market.”
Mark Pugh and Ger O’Carroll commented, “Galt provides Arrotek with access to markets, capabilities, and expertise previously unavailable to us. The combination with Galt will benefit existing customers of both companies, as well as provide Arrotek with opportunities to serve new segments of the market in Europe, North America and other global markets. Becoming part of the larger Theragenics organization also provides the resources to accelerate our growth and continue to expand.”